+データを開く
-基本情報
登録情報 | データベース: PDB / ID: 1agp | ||||||
---|---|---|---|---|---|---|---|
タイトル | THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLY-12 MUTANT OF P21-H-RAS | ||||||
要素 | C-H-RAS P21 PROTEIN | ||||||
キーワード | ONCOGENE PROTEIN | ||||||
機能・相同性 | 機能・相同性情報 GTPase complex / oncogene-induced cell senescence / positive regulation of ruffle assembly / negative regulation of GTPase activity / regulation of neurotransmitter receptor localization to postsynaptic specialization membrane / positive regulation of miRNA metabolic process / T-helper 1 type immune response / positive regulation of wound healing / defense response to protozoan / Signaling by RAS GAP mutants ...GTPase complex / oncogene-induced cell senescence / positive regulation of ruffle assembly / negative regulation of GTPase activity / regulation of neurotransmitter receptor localization to postsynaptic specialization membrane / positive regulation of miRNA metabolic process / T-helper 1 type immune response / positive regulation of wound healing / defense response to protozoan / Signaling by RAS GAP mutants / Signaling by RAS GTPase mutants / Activation of RAS in B cells / RAS signaling downstream of NF1 loss-of-function variants / SOS-mediated signalling / Activated NTRK3 signals through RAS / Activated NTRK2 signals through RAS / SHC1 events in ERBB4 signaling / GRB2 events in EGFR signaling / EGFR Transactivation by Gastrin / SHC1 events in EGFR signaling / positive regulation of protein targeting to membrane / Signalling to RAS / GRB2 events in ERBB2 signaling / SHC-related events triggered by IGF1R / Activated NTRK2 signals through FRS2 and FRS3 / Estrogen-stimulated signaling through PRKCZ / adipose tissue development / SHC1 events in ERBB2 signaling / SHC-mediated cascade:FGFR3 / MET activates RAS signaling / : / Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants / Signaling by PDGFRA extracellular domain mutants / Schwann cell development / SHC-mediated cascade:FGFR2 / PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases / SHC-mediated cascade:FGFR4 / Signaling by FGFR4 in disease / Erythropoietin activates RAS / SHC-mediated cascade:FGFR1 / protein-membrane adaptor activity / FRS-mediated FGFR3 signaling / positive regulation of epithelial cell proliferation / Signaling by FLT3 ITD and TKD mutants / FRS-mediated FGFR2 signaling / Signaling by FGFR3 in disease / FRS-mediated FGFR4 signaling / p38MAPK events / Tie2 Signaling / FRS-mediated FGFR1 signaling / Signaling by FGFR2 in disease / EPHB-mediated forward signaling / Signaling by FLT3 fusion proteins / FLT3 Signaling / Ras activation upon Ca2+ influx through NMDA receptor / myelination / Signaling by FGFR1 in disease / CD209 (DC-SIGN) signaling / NCAM signaling for neurite out-growth / Downstream signal transduction / Constitutive Signaling by Overexpressed ERBB2 / Insulin receptor signalling cascade / intrinsic apoptotic signaling pathway / Signaling by ERBB2 TMD/JMD mutants / small monomeric GTPase / positive regulation of MAP kinase activity / Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants / G protein activity / positive regulation of GTPase activity / VEGFR2 mediated cell proliferation / Constitutive Signaling by EGFRvIII / Signaling by ERBB2 ECD mutants / Signaling by ERBB2 KD Mutants / regulation of actin cytoskeleton organization / FCERI mediated MAPK activation / animal organ morphogenesis / positive regulation of JNK cascade / RAF activation / regulation of long-term neuronal synaptic plasticity / Signaling by high-kinase activity BRAF mutants / MAP2K and MAPK activation / Signaling by SCF-KIT / cellular senescence / cellular response to gamma radiation / positive regulation of fibroblast proliferation / Regulation of RAS by GAPs / RAS processing / Negative regulation of MAPK pathway / endocytosis / positive regulation of type II interferon production / Signaling by RAF1 mutants / Signaling by moderate kinase activity BRAF mutants / Paradoxical activation of RAF signaling by kinase inactive BRAF / Signaling downstream of RAS mutants / GDP binding / chemotaxis / MAPK cascade / Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants / Signaling by BRAF and RAF1 fusions / insulin receptor signaling pathway 類似検索 - 分子機能 | ||||||
生物種 | Homo sapiens (ヒト) | ||||||
手法 | X線回折 / 解像度: 2.3 Å | ||||||
データ登録者 | Franken, S.M. / Scheidig, A.J. / Wittinghofer, A. / Goody, R.S. | ||||||
引用 | ジャーナル: Biochemistry / 年: 1993 タイトル: Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras. 著者: Franken, S.M. / Scheidig, A.J. / Krengel, U. / Rensland, H. / Lautwein, A. / Geyer, M. / Scheffzek, K. / Goody, R.S. / Kalbitzer, H.R. / Pai, E.F. / Wittinghofer, A. #1: ジャーナル: Cell(Cambridge,Mass.) / 年: 1990 タイトル: Three-Dimensional Structures of H-Ras P21 Mutants: Molecular Basis for Their Inability to Function as Signal Switch Molecules 著者: Krengel, U. / Schlichting, I. / Scherer, A. / Schumann, R. / Frech, M. / John, J. / Kabsch, W. / Pai, E.F. / Wittinghofer, A. #2: ジャーナル: Embo J. / 年: 1990 タイトル: Refined Crystal Structure of the Triphosphate Conformation of H-Ras P21 at 1.35 Angstroms Resolution: Implications for the Mechanism of GTP Hydrolysis 著者: Pai, E.F. / Krengel, U. / Petsko, G.A. / Goody, R.S. / Kabsch, W. / Wittinghofer, A. | ||||||
履歴 |
|
-構造の表示
構造ビューア | 分子: MolmilJmol/JSmol |
---|
-ダウンロードとリンク
-ダウンロード
PDBx/mmCIF形式 | 1agp.cif.gz | 55.8 KB | 表示 | PDBx/mmCIF形式 |
---|---|---|---|---|
PDB形式 | pdb1agp.ent.gz | 40 KB | 表示 | PDB形式 |
PDBx/mmJSON形式 | 1agp.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
その他 | その他のダウンロード |
-検証レポート
文書・要旨 | 1agp_validation.pdf.gz | 457.3 KB | 表示 | wwPDB検証レポート |
---|---|---|---|---|
文書・詳細版 | 1agp_full_validation.pdf.gz | 460.8 KB | 表示 | |
XML形式データ | 1agp_validation.xml.gz | 5.9 KB | 表示 | |
CIF形式データ | 1agp_validation.cif.gz | 8.1 KB | 表示 | |
アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/ag/1agp ftp://data.pdbj.org/pub/pdb/validation_reports/ag/1agp | HTTPS FTP |
-関連構造データ
-リンク
-集合体
登録構造単位 |
| |||||||||
---|---|---|---|---|---|---|---|---|---|---|
1 |
| |||||||||
単位格子 |
| |||||||||
Components on special symmetry positions |
|
-要素
#1: タンパク質 | 分子量: 18933.227 Da / 分子数: 1 / 変異: G12D / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 参照: UniProt: P01112 |
---|---|
#2: 化合物 | ChemComp-MG / |
#3: 化合物 | ChemComp-GNP / |
#4: 水 | ChemComp-HOH / |
-実験情報
-実験
実験 | 手法: X線回折 |
---|
-試料調製
結晶 | マシュー密度: 1.97 Å3/Da / 溶媒含有率: 37.47 % |
---|
-データ収集
放射 | 散乱光タイプ: x-ray |
---|---|
放射波長 | 相対比: 1 |
反射 | *PLUS 最高解像度: 2.2 Å / Num. obs: 5195 / % possible obs: 59.2 % / Observed criterion σ(F): 0 / Num. measured all: 10475 / Rmerge F obs: 0.047 |
-解析
ソフトウェア |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
精密化 | 解像度: 2.3→8 Å / σ(F): 0 /
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
精密化ステップ | サイクル: LAST / 解像度: 2.3→8 Å
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
拘束条件 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ソフトウェア | *PLUS 名称: X-PLOR / 分類: refinement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
精密化 | *PLUS Num. reflection all: 4656 / Rfactor all: 0.177 / Rfactor Rwork: 0.177 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
溶媒の処理 | *PLUS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
原子変位パラメータ | *PLUS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
拘束条件 | *PLUS タイプ: x_angle_d / Dev ideal: 3.2 |